{"id":"W2767660506","doi":"10.1016/s0140-6736(17)32458-3","title":"Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial","year":2017,"lang":"en","type":"article","venue":"The Lancet","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":756,"is_retracted":false,"has_abstract":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"","keywords":"Rivaroxaban; Medicine; Aspirin; Placebo; Coronary artery disease; Cardiology; Internal medicine; Double blind; Anesthesia; Atrial fibrillation; Warfarin; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08657811531858285,"score_gpt":0.3517472701356689,"score_spread":0.265169154817086,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}